Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

arter of 2008, there is a lack of comparability in the per share amounts between the 2009 and 2008 periods presented.

                          CADENCE PHARMACEUTICALS, INC.
                          (a development stage company)
                             CONDENSED BALANCE SHEETS

                                                     March 31,   December 31,
                                                       2009          2008
                                                   (unaudited)
                      Assets
    Current assets:
      Cash and cash equivalents
                                                  $118,549,004   $47,627,246
      Restricted cash                                1,847,848     2,195,696
      Prepaid expenses and other current assets        312,801       219,674
        Total current assets                       120,709,653    50,042,616

    Property and equipment, net                      4,376,590     4,477,020
    Restricted cash                                    537,586       537,586
    Other assets                                        57,673        90,792
        Total assets                              $125,681,502   $55,148,014

            Liabilities and Stockholders' Equity
    Current liabilities:
      Accounts payable                              $3,542,647    $4,877,854
      Accrued liabilities                            5,814,540     9,063,310
      Current portion of long-term debt              7,045,605     7,694,173
      Current current liabilities                       22,048        22,048
        Total current liabilities                   16,424,840    21,657,385

    Deferred rent                                      876,724       952,274
    Long-term debt, less current portion and
     discount                                        4,653,728     6,098,113
    Total stockholders' equity                     103,726,210    26,44
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
2. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... an exclusive license for technology developed by the ... expression in plants, including for applications in production of ... The technology was developed under the direction of ... Kultevat and former president of the Danforth Plant Science ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... Eli Lilly and Company,(NYSE: LLY ) today announced ... as a Distinguished Lilly Scholar focusing on schizophrenia,and other ... Dr. Conley join our team here at,Lilly," said Jack ... well-known thought leader, clinician and scientist who brings,important experience ...
... REINACH, Switzerland, December 14 As reported,in September, ... at this,year,s Interscience Conference on Antimicrobial Agents and ... at ICAAC, that was,supported through an educational grant ... The symposium is entitled "Treatment of Methicillin-resistant,Staphylococcus ...
... Bradley,Pharmaceuticals, Inc. (NYSE: BDY ) today announced ... the topical treatment of,external genital (EGW) and perianal ... older. Veregen(TM) is the first new,prescription treatment for ... product from MediGene AG (Frankfurt: MDG) and has ...
Cached Biology Technology:Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar 2Arpida-Supported CME Symposium Available Online 2Arpida-Supported CME Symposium Available Online 3Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 2Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 3Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 4Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 5Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 6
(Date:9/17/2014)... A UT Arlington engineering professor and his doctoral student ... that can accumulate water collected from fog and dew., ... the world or deserts around the globe., Cheng Luo, ... Xin Heng, PhD candidate in the same College of ... Aug. 25 edition of ACS, (American Chemical Society) ...
(Date:9/17/2014)... 2014) A rare genetic disorder known as Jacobsen syndrome ... joint investigation by researchers at San Diego State University ... to suggesting better treatment options for people with Jacobsen ... genetic underpinnings of autism., Jacobsen syndrome affects approximately 1 ... Health. It occurs in a person when there is ...
(Date:9/17/2014)... shopping bags and their environmental impact recently scored a ... statewide ban on the bags, and Governor Jerry Brown ... industry is not yielding without a fight, according to ... the weekly newsmagazine of the American Chemical Society. , ... the anti-bag campaign logged its first small victory in ...
Breaking Biology News(10 mins):Shorebird's beak inspires UT Arlington research on water collection 2A link between Jacobsen syndrome and autism 2
... convey vital medical information, but the sight of a needle ... developed by a team of researchers in Israel, however, can ... in real-time, simply by shining a light through the skin. ... to provide high-resolution images of blood coursing through our veins ...
... differences in bacterial colonization of the infant gut in formula-fed ... genes involved in the infant,s immune system. The study, ... access journal Genome Biology , is an Editor,s Pick. ... Texas A&M University, Miami University, and University of Arkansas scientists. ...
... of scientists from the National University of Singapore,s (NUS) Department ... drug-led compound a compound that is undergoing preclinical trials ... energy and stop them from growing into a tumour. This ... first time a research group has provided evidence showing how ...
Cached Biology News:New microscope uses rainbow of light to image the flow of individual blood cells 2New microscope uses rainbow of light to image the flow of individual blood cells 3Breast-fed babies' gut microbes contribute to healthy immune systems 2Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2
... Pierce offers maleimide activated carrier proteins ... conjugates. Imject Maleimide Activated Carrier Proteins ... been preactivated with a heterobifunctional cross-linker ... stable, sulfhydryl-reactive carrier protein. Thus ...
...
... A perfect complement to high-speed analytical techniques, the AutoTrace SPE is a ... automates the cartridge conditioning, sample loading and elution steps for large volumes aqueous ... ... ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Biology Products: